The cyclic nucleotide-gated channel alpha 2 (CNGA2) antibody is a crucial tool for studying the CNGA2 subunit, a key component of cyclic nucleotide-gated (CNG) ion channels. CNGA2. predominantly expressed in olfactory sensory neurons, forms heterotetrameric channels with CNGB1b subunits, enabling the detection of odorants by converting chemical signals into electrical responses. These channels are activated by cyclic nucleotides (e.g., cAMP or cGMP), playing a pivotal role in olfactory signal transduction and sensory perception.
CNGA2 antibodies are widely used to investigate the expression, localization, and function of CNGA2 in physiological and pathological contexts. They facilitate techniques such as Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels in tissues like the olfactory epithelium, brain, and retina. Research using these antibodies has linked CNGA2 dysfunction to olfactory deficits, neurodegenerative disorders (e.g., Alzheimer’s and Parkinson’s diseases), and certain cancers, highlighting its broader regulatory roles beyond sensory systems.
Developed in various host species (e.g., rabbit, mouse), CNGA2 antibodies are validated for specificity via knockout controls. Their applications extend to studying channel assembly, post-translational modifications, and interactions with signaling pathways. As CNGA2 is critical for maintaining cellular excitability and calcium homeostasis, its antibody serves as a vital reagent in neuroscience, molecular biology, and drug discovery, aiding in the exploration of sensory mechanisms and therapeutic targets.